Predictive Value of Osteopontin and Inflammatory Factors in the Progression of Mild Cognitive Impairment

doi:10.12114/j.issn.1007-9572.2018.00.283

Abstract

Abstract: Objective　To evaluate the predictive value of osteopontin（OPN） and inflammatory cytokines in the progression of mild cognitive impairment （MCI） to Alzheimer's disease（AD）．Methods　Prospective analysis of 60 patients with MCI and 60 patients with non-inflammatory neuropathy （OND） matched by age and sex admitted to Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region from June 2015 to June 2017 was carried out.The clinical data were collected and condition assessment evaluated by MMSE score.Enzyme linked immunosorbent assay （ELISA） was used to measure the levels of OPN in cerebrospinal fluid （CSF） and serum，interleukin（IL）-1β，IL-6，IL-17A，transforming growth factor （TGF）-β1 and tumor necrosis factor （TNF）-α.All patients were followed up for 1 year.According to whether the disease progressed to AD，subjects were divided into AD group，no-progression group and OND group.Serum OPN level and inflammatory factors were measured again in patients of AD group during follow-up.Results　There were 23 cases in AD group，32 cases in no-progression group and 51 cases in OND group.The level of CSF OPN in AD group was significantly higher than that in no-progression group and OND group （P<0.05）．There was no significant difference in the levels of IL-1β，IL-6，IL-17A，TGF-β1 and IL-4 among three groups after 1 year of follow-up （P>0.05）；the levels of serum OPN and TNF-α in three groups at 1 year of follow-up were statistically significant （P<0.05）；the levels of OPN and TNF-α in AD group were higher than those in no-progression group and OND group （P<0.05）．The result of correlation analysis showed that the levels of OPN in cerebrospinal fluid and in serum were positively correlated with MMSE score at admission （r=0.348，P<0.001；r=0.631，P<0.001），and the level of TNF-α in serum was negatively correlated with MMSE score （r=-0.435，P<0.001）．There were significant differences in MMSE score，CSF OPN and serum OPN in AD group at admission，at diagnosis of AD and after one-year follow-up （P<0.001），as MMSE score was lower at the time of diagnosis of AD and follow-up for one year，and the levels of OPN in cerebrospinal fluid and serum were higher after admission （P<0.05）．Conclusion　CSF OPN level is a potential biomarker for the early identification of MCI which may progress to AD.Serum and CSF OPN and TNF-α were associated with the severity of dementia in AD.

Key words: Alzheimer disease, Mild cognitive impairment, Osteopontin, Inflammation mediators, Correlation analysis

摘要： 目的　评估骨桥蛋白（OPN）以及炎性因子在轻度认知障碍（MCI）患者进展为阿尔茨海默病（AD）中的预测价值。方法　前瞻性分析2015年6月—2017年6月新疆维吾尔自治区中医医院脑病一科收治的MCI患者以及年龄、性别相匹配的非炎症性神经病变（OND）患者，各60例。收集患者临床资料并对其进行病情评估，采用酶联免疫吸附试验（ELISA）检测患者脑脊液和血清OPN水平、血清白介素（IL）-1β、IL-6、IL-17A、转化生长因子（TGF）-β1、肿瘤坏死因子（TNF）-α和IL-4水平。对患者通过门诊和住院随访1年，根据患者在随访结束时的诊断分为AD组、未进展组和OND组。再次检测随访结束时AD组患者血清OPN以及炎性因子水平。结果　随访结束时AD组23例，未进展组32例，OND组51例。入院时3组脑脊液OPN水平比较，差异有统计学意义（P<0.05）；其中AD组脑脊液OPN水平高于未进展组和OND组（P<0.05）。随访1年时，3组IL-1β、IL-6、IL-17A、TGF-β1、IL-4水平比较，差异均无统计学意义（P>0.05）；随访1年时3组血清OPN、TNF-α水平比较，差异均有统计学意义（P<0.05）；其中AD组血清OPN、TNF-α水平均高于未进展组和OND组（P<0.05）。相关性分析结果显示，所有患者入院时脑脊液OPN、血清OPN水平与MMSE评分呈正相关（r=0.348，P<0.001；r=0.631，P<0.001），血清TNF-α水平与MMSE评分呈负相关（r=-0.435，P<0.001）。AD组患者入院时、诊断AD时、随访1年时MMSE评分、脑脊液OPN、血清OPN水平比较，差异均有统计学意义（P<0.001）；其中诊断AD时、随访1年时MMSE评分低于入院时，脑脊液OPN、血清OPN水平高于入院时（P<0.05）。结论　脑脊液OPN水平是早期识别进展为AD的MCI患者的潜在生物标志物，并且血清及脑脊液OPN水平以及TNF-α与AD的痴呆严重程度具有相关性。

关键词: 阿尔茨海默病, 轻度认知障碍, 骨桥蛋白质, 炎症介导素类, 相关性分析

LIU Ting,LI Dan,ZHANG Yan, et al. Predictive Value of Osteopontin and Inflammatory Factors in the Progression of Mild Cognitive Impairment[J]. Chinese General Practice, 2018, 21(32): 3933-3937. DOI: 10.12114/j.issn.1007-9572.2018.00.283.
刘婷,李丹,张燕等. 骨桥蛋白及炎性因子在轻度认知障碍进展的预测价值研究[J]. 中国全科医学, 2018, 21(32): 3933-3937. DOI: 10.12114/j.issn.1007-9572.2018.00.283.

References

［1］MARTINELLI J E，CECATO J F，MARTINELLI M O，et al．Performance of the Pentagon Drawing test for the screening of older adults with Alzheimer's dementia［J］．Dement Neuropsychol，2018，12（1）：54-60．DOI：10.1590/1980-57642018dn12-010008.3937
［2］IMAI R，HORI H，ITOH M，et al．Inflammatory markers and their possible effects on cognitive function in women with posttraumatic stress disorder［J］．J Psychiatr Res，2018，102（3）：192-200．DOI：10.1016/j.jpsychires.2018.04.009.3937
［3］MARTIN E，DELARASSE C.Complex role of chemokine mediators in animal models of Alzheimer's disease［J］．Biomed J，2018，41（1）：34-40．DOI：10.1016/j.bj.2018.01.002.3937
［4］TORIKA N，ASRAF K，APTE R N，et al．Candesartan ameliorates brain inflammation associated with Alzheimer's disease［J］．CNS Neurosci Ther，2018，24（3）：231-242．DOI：10.1111/cns.12802.3937
［5］MCKHANN G M，KNOPMAN D S，CHERTKOW H，et al．The diagnosis of dementia due to Alzheimer's disease：recommendations from the National Institute on Aging Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease［J］．Alzheimers Dement，2011，7（3）：263-269．DOI：10.1016/j.jalz.2011.03.005.3937
［6］KARPENKO M N，VASILISHINA A A，GROMOVA E A，et al．Interleukin-1β，interleukin-1 receptor antagonist，interleukin-6，interleukin-10，and tumor necrosis factor-α levels in CSF and serum in relation to the clinical diversity of Parkinson's disease［J］．Cell Immunol，2018，327：77-82．DOI：10.1016/j.cellimm.2018.02.011.3937
［7］GASPAROTTO J，GIRARDI C S，SOMENSI N，et al．Receptor for advanced glycation end products mediates sepsis-triggered amyloid-β accumulation，Tau phosphorylation，and cognitive impairment［J］．J Biol Chem，2018，293（1）：226-244．DOI：10.1074/jbc.M117.786756.3937
［8］PATERSON R W，HEYWOOD W E，HESLEGRAVE A J，et al．A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology［J］．Transl Psychiatry，2016，6（11）：e952．DOI：10.1038/tp.2016.194.3937
［9］WANG J，LI X B，HUANG P，et al．Change of peripheral blood treg/Thl7 in cognitive impairment with chronic renal failure patients［J］．Cell Physiol Biochem，2018，45（1）：281-290．DOI：10.1159/000486809.3937
［10］AILANE S，LONG P，JENNER P，et al．Expression of integrin and CD44 receptors recognising osteopontin in the normal and LPS-lesioned rat substantia nigra［J］．Eur J Neurosci，2013，38（3）：2468-2476．DOI：10.1111/ejn.12231.3937
［11］SCHJ?NNING NIELSEN M，SIMONSEN A H，SIERSMA V，et al．Are CSF biomarkers useful as prognostic indicators in diagnostically unresolved cognitively impaired patients in a normal clinical setting［J］．Dement Geriatr Cogn Dis Extra，2016，6（3）：465-476．DOI：10.1159/000449410.3937
［12］何璐，王瑛，徐玮，等．基于血浆免疫及炎症相关蛋白的阿尔茨海默病筛查标志物的研究［J］．上海交通大学学报（医学版），2017，37（7）：950-954.3937
HE L，WANG Y，XU W，et al．Study on screening markers of Alzheimer's disease based on plasma immunity and inflammation-related proteins［J］．Journal of Shanghai Jiaotong University（Medical Sciences），2017，37（7）：950-954.3937
［13］D'ANNA L，ABU-RUMEILEH S，FABRIS M，et al．Serum interleukin-10 levels correlate with cerebrospinal fluid amyloid beta deposition in Alzheimer disease patients［J］．Neurodegener Dis，2017，17（5）：227-234．DOI：10.1159/000474940.3937
［14］KIM Y S，LEE K J，KIM H，et al．Serum tumour necrosis factor-α and interleukin-6 levels in Alzheimer's disease and mild cognitive impairment［J］．Psychogeriatrics，2017，17（4）：224-230．DOI：10.1111/psyg.12218.3945
［15］ZHU Y，CHAI Y L，HILAL S，et al．Serum IL-8 is a marker of white-matter hyperintensities in patients with Alzheimer's disease［J］．Alzheimers Dement（Amst），2017，7（1）：41-47．DOI：10.1016/j.dadm.2017.01.001.3945
［16］STEELAND S，GORLé N，VANDENDRIESSCHE C，et al．Counteracting the effects of TNF receptor-1 has therapeutic potential in?Alzheimer's disease［J］．EMBO Mol Med，2018，10（4）：e8300．DOI：10.15252/emmm.201708300.3945
［17］EKERT J O，GOULD R L，REYNOLDS G，et al．TNF alpha inhibitors in Alzheimer's disease：a systematic review［J］．Int J Geriatr Psychiatry，2018，33（5）：688-694．DOI：10.1002/gps.4871.3945
［18］COMI C，CARECCHIO M，CHIOCCHETTI A，et al．Osteopontin is increased in the cerebrospinal fluid of patients with Alzheimer's disease and its levels correlate with cognitive decline［J］．J Alzheimers Dis，2010，19（4）：1143-1148．DOI：10.3233/JAD-2010-1309.3945
［19］SIMONSEN A H，MCGUIRE J，HANSSON O，et al．Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment［J］．Arch Neurol，2007，64（3）：366-370.3945
［20］BEGCEVIC I，BRINC D，BROWN M，et al．Brain-related proteins as potential CSF biomarkers of Alzheimer's disease：a targeted mass spectrometry approach［J］．J Proteomics，2018，182（3）：12-20．DOI：10.1016/j.jprot.2018.04.027.3945
［21］SUN Y，YIN X S，GUO H，et al．Elevated osteopontin levels in mild cognitive impairment and Alzheimer's disease［J］．Mediators Inflamm，2013：615745．DOI：10.1155/2013/615745.3945
［22］JULIAN A，RIOUX-BILAN A，RAGOT S，et al．Blood inflammatory mediators and cognitive decline in Alzheimer's disease：a two years longitudinal study［J］．J Alzheimers Dis，2018，63（1）：87-92.3945
［23］MAZAHERI N，PEYMANI M，GALEHDARI H，et al．Ameliorating effect of osteopontin on H2O2-induced apoptosis of human oligodendrocyte progenitor cells［J］．Cell Mol Neurobiol，2018，38（4）：891-899．DOI：10.1007/s10571-017-0563-4.3945
［24］YU H，LIU X，ZHONG Y.The effect of osteopontin on microglia［J］．Biomed Res Int，2017：1879437．DOI：10.1155/2017/1879437.3945

[1]	XIN Gongkai, CONG Xin, YUAN Lei, CHENG Yuetong, NI Cuiping, ZHANG Weiwei, ZHANG Pingping, LIU Yu. Research Progress on Comprehensive Assessment Tools for the Elderly with Dementia [J]. Chinese General Practice, 2023, 26(33): 4103-4109.
[2]	ZHOU Sijing, LUO Bangan, CAO Hui, ZHANG Xi, WANG Dongxin. Epidemiological Characteristics of Dementia and Its Correlation with Multimorbidity among Residents Aged 65 and Above [J]. Chinese General Practice, 2023, 26(29): 3616-3621.
[3]	CHEN Weixiang, YIN Renlin, LING Lin, ZHANG Chi, JIANG Tingbo, LIN Jia. Correlation between C-reactive Protein to Albumin and Coronary Collateral Circulation in Patients with Unstable Angina Pectoris [J]. Chinese General Practice, 2023, 26(27): 3430-3434.
[4]	LI Zimeng, WANG Rong, CHEN Shuai, ZHAO Caili, WANG Xiaocong, WEN Yalu, LIU Long. Application of metaPRS and APOEε4 to Optimize Genetic Risk Prediction Modeling Strategy for Mild Cognitive Impairment [J]. Chinese General Practice, 2023, 26(25): 3104-3111.
[5]	ZUMURETI ·Abudukeyimu, MA Yanlin, ZHU Kairui, LIU Fang, LI Xia. Correlation of Early Growth Response 3 and Interleukin 6 Expression Levels with Coronary Heart Disease [J]. Chinese General Practice, 2023, 26(24): 3016-3021.
[6]	DING Xiaoyun, JIN Juzhen, YANG Jin, ZHOU Jing, HU Jin, MENG Yue, LIANG Xiaoxian, GAI Yun, WANG Junhua, WANG Ziyun. The Mediating Effect of Waist Circumference and Fasting Plasma Glucose on the Association between Obstructive Sleep Apnea Syndrome and Arterial Stiffness in a Population Aged 40-65 Years [J]. Chinese General Practice, 2023, 26(21): 2597-2602.
[7]	YU Yanxue, BAI Ruyu, YU Wenlong, GUO Xia, WU Li'e. Occurrence Status and Influencing Factors of Cognitive Dysfunction in Population Aged 60 and Above [J]. Chinese General Practice, 2023, 26(21): 2581-2588.
[8]	ZHOU Shiyu, CHEN Shaolin, DENG Renli, DAI Mi, LIU Tao, TIAN Kunming. The Association and Predictive Value of Lipid Ratios to Metabolic Syndrome: a Multistage Cross-sectional Study [J]. Chinese General Practice, 2023, 26(21): 2589-2596.
[9]	XU Bixia, YAO Weiguang. Changes in Patient Visits and Associated Determinants in Primary Healthcare Settings in Guangdong: a Grey Relational Analysis [J]. Chinese General Practice, 2023, 26(16): 1965-1971.
[10]	MA Yunyun, SONG Yulei, LIANG Xiao, GAO Jiaojiao, QI Xinru, WANG Ye, XU Guihua, BAI Yamei. Value of Reduced Taste Recognition Ability in Early Warning of Mild Cognitive Impairment [J]. Chinese General Practice, 2023, 26(16): 1984-1988,2003.
[11]	DONG Linrui, CHANG Qingqing, MA Jianjun, LIU Chuanze, GUO Dashuai, LI Xiaohuan, FAN Yongyan, LI Dongsheng. Correlation between Autonomic Dysfunction and Cognitive Impairment in Patients with Parkinson's Disease [J]. Chinese General Practice, 2023, 26(12): 1450-1455,1471.
[12]	WEI Zhuqin, ZHANG Ruoyu, ZHANG Chen, SU Liming, HUANG Cheng, ZHANG Junwei, QIAN Mincai, QI Hengnian, WANG Lina. Characteristics and Application Value of Handwriting in Elderly Patients with Mild Cognitive Impairment [J]. Chinese General Practice, 2023, 26(10): 1224-1233.
[13]	MA Wanrui, LI Manna, WANG Liqun, WANG Zhizhong. Influencing Factors of Hypertension Combined with Mild Cognitive Impairment in Community Population over 55 Years [J]. Chinese General Practice, 2023, 26(09): 1075-1079.
[14]	YANG Haopeng, SUO Jingdong, SHEN Xianlei, WANG Dan, ZHU Xuemin, LIU Yuehua, LIANG Wannian. A Recommended "Dementia Prevention and Treatment Action Plan" Task List for China: WHO Global Action Perspective [J]. Chinese General Practice, 2023, 26(07): 775-779.
[15]	TAO Shuai, HAN Xing, KONG Liwen, WANG Zumin, XIE Haiqun. Machine Learning-based Gait Analysis for Recognition of Amnestic Mild Cognitive Impairment and Alzheimer's Disease [J]. Chinese General Practice, 2022, 25(31): 3857-3865.